Circio, the most advanced company in Europe in circRNA technology, is setting up in new facilities in Flemingsberg

The Norwegian company, Circio Holding ASA, has established a Swedish subsidiary, Circio AB, in Flemingsberg, and they have recently expanded their facilities. The research group and activity level at the Karolinska Institutet grew, necessitating their acquisition of their own labs and offices at A Working Lab in Flemingsberg.

Circio is developing gene therapy and vaccines with a unique circular RNA (circRNA) platform. Their goal is to improve medicines for various applications, including genetic diseases, infectious diseases, and cancer therapy. Since 2022, their research and development activities have been based in Flemingsberg, where they collaborate closely with Prof. Michael Uhlin at the Karolinska Institutet. Recently, they have expanded their resources by acquiring their own lab spaces at A Working Lab (AWL) in Flemingsberg while continuing their valuable partnership with the Karolinska Institutet.

– The type of RNA that is receiving the most investment right now is circular RNA, and Circio is the most advanced company in Europe in circRNA technology. We have developed a circRNA concept that has demonstrated a 15x extended shelf life compared to mRNA, says Erik Digman Wiklund, CEO of Circio.

Erik continuous to explain that there were challenges with the use of mRNA technology despite its success in COVID vaccines. However, these challenges are addressed by circular RNA, which has the potential to become a prominent solution in the future.

Competent workforce and Infrastructure

Furthermore, Erik believes there were several reasons why Circio established itself in Flemingsberg. He mentions that Norway does not have as well-established pharmaceutical industry as they have in Sweden and Denmark. Additionally, Flemingsberg offers a strong research infrastructure and a competent workforce.

– We are in Flemingsberg due to the availability of a skilled workforce in this sector and its infrastructure. Furthermore, we could find a lab right next to the Karolinska Institutet, which also has excellent infrastructure, says Erik.

Erik also notes that it can be costly for smaller companies to build their own laboratories from scratch, especially with the level of security and advanced equipment that is required. By utilizing the existing and equipped laboratories offered by AWL, Circio could expand its operations while benefiting from the advantages of Flemingsberg.

Agnes Török: A Voice for Performance Poetry & Reading Promotion

With roots in Sweden and an international career, Agnes Török has established themselves as one of the most engaging voices in modern poetry. Agnes Török is Sweden's Reading Ambassador, a spoken word poet, and an author. Recently, they were also appointed as the lead instructor for the new university program in Performance Poetry and Storytelling at the Stockholm Institute of Music Education (SMI).

ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.

GameHub Flemingsberg: A New Initiative to Create the Gaming Cluster of the Future

The Flemingsberg Science Foundation is launching a business development program in collaboration with Drivhuset Stockholm, associated partners, and Södertörn University as a first step in establishing a gaming cluster in Flemingsberg. The project, named GameHub, aims to facilitate the creation of new gaming companies and strengthen Flemingsberg's position as a center for game development.

12 Next